Oct 2023 $30 M No. 5 $10 to $50 million 2
Amicus Therapeutics Inc.: Raise no. 5, Oct 2023 × Investors in this round 2 investors had bought by the notice of Oct 16, 2023: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $30 M of $30 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bradley Campbell · Executive Officer, Director · President and Chief Executive Officer of the Issuer David Clark · Executive Officer · Chief People Officer Ellen S. Rosenberg · Executive Officer · Chief Legal Officer and Corporate Secretary Jeffrey P. Castelli, Ph.D. · Executive Officer · Chief Development Officer Simon Harford · Executive Officer · Chief Financial Officer Burke W Whitman · Director Craig A Wheeler · Director Eiry W Roberts, M.D. · Director Glenn P Sblendorio · Director John F Crowley · Director Lynn D Bleil · Director Margaret G. McGlynn · Director Michael A Kelly · Director Michael G Raab · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Simon Harford, Chief Financial Officer of Issuer. Source: SEC Form D, newest notice filed Oct 16, 2023. Read the notice at the SEC .
equity SEC Sep 2021 $200 M No. 4 $50 to $250 million 9
Amicus Therapeutics Inc.: Raise no. 4, Sep 2021 × Investors in this round 9 investors had bought by the notice of Oct 13, 2021: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $200 M of $200 M offered
Smallest investment taken $2,149,996
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Over $100 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bradley L. Campbell · Executive Officer, Director · President and Chief Operating Officer of the Issuer Daphne L. Quimi · Executive Officer · Chief Financial Officer of the Issuer David M. Clark · Executive Officer · Chief People Officer of the Issuer Ellen S. Rosenberg · Executive Officer · Chief Legal Officer and Corporate Secretary of the Issuer John F. Crowley · Executive Officer, Director · Chief Executive Officer of Issuer Samantha M. Prout · Executive Officer · Vice President and Global Controller Burke W. Whitman · Director Craig A. Wheeler · Director Eiry L. Roberts · Director Glenn P. Sblendorio · Director Lynn D. Bleil · Director Margaret G. McGlynn · Director Michael A. Kelly · Director Michael G. Raab · Director Robert D. Essner · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Daphne Quimi, Chief Financial Officer of the Issuer. Source: SEC Form D, newest notice filed Oct 13, 2021. Read the notice at the SEC .
equity, options SEC Jul 2016 $5 M Issued in a merger or acquisition $2 to $10 million 18
Amicus Therapeutics Inc.: Private sale, Jul 2016 × Investors in this round 18 investors had bought by the notice of Jul 19, 2016: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $5,000
Finders' fees $5,000
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Daphne D. Quimi · Executive Officer John Crowley · Executive Officer, Director William D. Baird, III · Executive Officer Craig A. Wheeler · Director Donald J. Hayden, Jr. · Director Glen G. Sblendorio · Director Margaret G. McGlynn · Director Michael G. Raab · Director Robert D. Essner · Director Sol D. Barer · Director Ted W. Love · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Ellen S. Rosenberg, General Counsel and Corporate Secretary. Source: SEC Form D, newest notice filed Jul 19, 2016. Read the notice at the SEC .
equity SEC Nov 2013 $15 M No. 3 $10 to $50 million 5
Amicus Therapeutics Inc.: Raise no. 3, Nov 2013 × Investors in this round 5 investors had bought by the notice of Dec 3, 2013: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $15 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bradley L. Campbell · Executive Officer Daphne W. Quimi · Executive Officer David J. Lockhart · Executive Officer Enrique R. Dilone · Executive Officer Jayne W. Gerskowitz · Executive Officer Jeffrey P. Castelli · Executive Officer Joan C. Winterbottom · Executive Officer John F. Crowley · Executive Officer, Director John R. Kirk · Executive Officer Ken R. Valenzano · Executive Officer Kenneth W. Peist · Executive Officer William D. Baird, III · Executive Officer Donald J. Hayden, Jr. · Director Glenn G. Sblendorio · Director James J. Barrett · Director James N. Topper · Director Margaret G. McGlynn · Director Michael G. Raab · Director Robert W. Essner · Director Sol J. Barer · Director Ted W. Love · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by William D. Baird III, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 3, 2013. Read the notice at the SEC .
equity, options SEC Nov 2013 $15 M Issued in a merger or acquisition $10 to $50 million 29
Amicus Therapeutics Inc.: Private sale, Nov 2013 × Investors in this round 29 investors had bought by the notice of Dec 3, 2013: 29 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $15 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bradley L. Campbell · Executive Officer Daphne W. Quimi · Executive Officer David J. Lockhart · Executive Officer Enrique R. Dilone · Executive Officer Jayne W. Gerskowitz · Executive Officer Jeffrey W. Castelli · Executive Officer Joan C. Winterbottom · Executive Officer John F. Crowley · Executive Officer, Director John R. Kirk · Executive Officer Ken R. Valenzano · Executive Officer Kenneth W. Peist · Executive Officer William D. Baird, III · Executive Officer Donald J. Hayden, Jr. · Director Glenn G. Sblendorio · Director James J. Barrett · Director James N. Topper · Director Margaret G. McGlynn · Director Michael G. Raab · Director Robert W. Essner · Director Sol J. Barer · Director Ted W. Love · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by William D. Baird, III, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 3, 2013. Read the notice at the SEC .
equity SEC Jul 2012 $19 M No. 2 $10 to $50 million 1
Amicus Therapeutics Inc.: Raise no. 2, Jul 2012 × Investors in this round 1 investor had bought by the notice of Jul 30, 2012: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $19 M of $19 M offered
Smallest investment taken $18,582,360
What was sold equity
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bradley L. Campbell · Executive Officer Daphne W. Quimi · Executive Officer David J. Lockhart · Executive Officer Enrique R. Dilone · Executive Officer John F. Crowley · Executive Officer, Director John R. Kirk · Executive Officer Ken R. Valenzano · Executive Officer Kenneth W. Peist · Executive Officer Pol F. Boudes · Executive Officer Robert W. Winkler · Executive Officer William D. Baird, III · Executive Officer Donald J. Hayden, Jr. · Director Glenn G. Sblendorio · Director James J. Barrett · Director James N. Topper · Director Margaret G. McGlynn · Director Michael G. Raab · Director Robert W. Essner · Director Sol J. Barer · Director Ted W. Love · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “A sale of unregistered shares was made to one accredited investor.”Signed by John F. Crowley, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 30, 2012. Read the notice at the SEC .
equity SEC Oct 2010 $31 M No. 1 $10 to $50 million 1
Amicus Therapeutics Inc.: Raise no. 1, Oct 2010 × Investors in this round 1 investor had bought by the notice of Nov 5, 2010: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $31 M of $31 M offered
Smallest investment taken $31,284,583
What was sold equity
Meant to last a year or less
Issuer's revenue $25 million to $100 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bradley L Campbell · Executive Officer David R Lockhart · Executive Officer Geoffrey P Gilmore · Executive Officer John F Crowley · Executive Officer, Director · Chairman and Chief Executive Officer John R Kirk · Executive Officer Ken R Valenzano · Executive Officer Matthew R Patterson · Executive Officer Pol F Boudes · Executive Officer S Nicole Schaeffer · Executive Officer Alexander E Barkas · Director Donald J Hayden · Director Glenn P Sblendorio · Director James N Topper · Director James R Barrett · Director Margaret G McGlynn · Director Michael G Raab · Director P Sherrill Neff · Director Sol J Barer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “A sale of unregistered shares was made to one accredited investor.”Signed by Geoffrey P. Gilmore, General Counsel and Secretary. Source: SEC Form D, newest notice filed Nov 5, 2010. Read the notice at the SEC .
equity SEC